Clinical Trials · NCT06490328

Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer

CompletedPhase 3Gonadorelin (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Dongkook Pharmaceutical Co., Ltd.
Enrollment
161
Start date
May 2024
Locations
8 sites, South Korea
Primary endpoint
Percentage of participants
View Gonadorelin compound reference